Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Chronic and Recurrent Erythema Nodosum Leprosum
NCT04822909Phase 4Completed
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Sep 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of apremilast in erythema nodosum leprosum (ENL), sponsored by Post Graduate Institute of Medical Education and Research. Started Sep 2019; status: completed.
02
Drugs
apremilast
03
Conditions
erythema nodosum leprosum (ENL)
Beyond the preview
Go deeper on NCT04822909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04822909.